Calle José Isbert, 2
Pozuelo de Alarcón
Madrid 28223
Spain
34 91 021 30 00
https://www.rovi.es
Settore/i:
Settore:
Impiegati a tempo pieno: 1.993
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Juan Lopez-Belmonte Encina | President & CEO | 1,15M | N/D | N/D |
Mr. Ivan Lopez-Belmonte Encina | Second Deputy Chairman & Head of Corporate Development | 462k | N/D | N/D |
Mr. Javier Lopez-Belmonte Encina | First Deputy Chairman & CFO | 466k | N/D | N/D |
Marta Campos Martínez | Head of Investor Relations | N/D | N/D | N/D |
Ms. Mercedes Benítez del Castillo Sánchez | Legal Department Manager | N/D | N/D | N/D |
Mr. Fernando Martínez Morales | Director of Sales | N/D | N/D | N/D |
Ms. Rosario Perucha Pérez | Marketing Manager | N/D | N/D | N/D |
Mr. Francisco Javier Angulo García | Human Resources Manager | N/D | N/D | N/D |
Mr. Gabriel Nunez Fernandez | Secretary | N/D | N/D | N/D |
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are licensed from other laboratories. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It provides non-prescription pharmaceutical products; and contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
L'ISS Governance QualityScore di Laboratorios Farmaceuticos Rovi, S.A. al 1 dicembre 2023 è 4. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 7; diritti degli azionisti: 7; retribuzione: 1.